Peter D Senter

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

P. Burke, P. Senter, Joseph Z. Hamilton, 2016, Molecular Cancer Therapeutics.

Antibody-drug conjugates: targeted drug delivery for cancer.

Stephen C Alley, P. Senter, S. Alley, 2010, Current opinion in chemical biology.

Efficient cancer therapy with a nanobody-based conjugate.

Serge Muyldermans, Natalija Backmann, Patrick De Baetselier, 2004, Cancer research.

Arming antibodies: prospects and challenges for immunoconjugates

Anna M Wu, A. Wu, P. Senter, 2005, Nature Biotechnology.

Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates

Matthew R. Levengood, Kim K. Emmerton, T. Lewis, 2016, Angewandte Chemie.

Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.

Martha Anderson, P. Burke, P. Senter, 2009, Bioorganic & medicinal chemistry letters.

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

P. Senter, J. Hunter, S. Doronina, 2014, Nature Biotechnology.

A model of molecular interactions on short oligonucleotide microarrays

K. Aldape, M. Miles, Li Zhang, 2003, Nature Biotechnology.

Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.

J. Drachman, P. Senter, Jonathan G Drachman, 2013, Hematology. American Society of Hematology. Education Program.

Antibody-drug conjugates in cancer therapy.

P. Carter, P. Senter, Eric L Sievers, 2013, Annual review of medicine.